BioSpace News Archive

Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that Lisa Ricciardi , president and chief executive officer will participate on a panel during Cantor Fitzgerald’s virtual Brain Week 2023 conference, which will be held June 20-23, 2023.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Zevra Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000 ® Index and small-cap Russell 2000 ® Index in accordance with the 2023 Russell indexes annual reconstitution.

DiagnaMed Holdings Corp. is pleased to announce an update of CERVAI™, the Company’s proprietary AI brain health platform.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM a Phase 3 clinical trial comparing aficamten as monotherapy to metoprolol as monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP).

CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study.

Oramed Pharmaceuticals Inc. announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association’s 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.

HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’) announced today that the first patient has been enrolled in the Olive trial, a randomized, double-blind, placebo-controlled trial in more than 300 patients with Major Depressive Disorder (MDD) conducted in eight countries in Europe.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced a multi-level collaboration agreement with the Molecular Biology Institute of Paraná (IBMP) in Brazil.